|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US7695734||BOEHRINGER INGELHEIM||Extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof|| |
(4 years from now)
|US8679533||BOEHRINGER INGELHEIM||Pramipexole once-daily dosage form|| |
(5 years from now)
Mirapex Er is owned by Boehringer Ingelheim.
Mirapex Er contains Pramipexole Dihydrochloride.
Mirapex Er has a total of 2 drug patents out of which 0 drug patents have expired.
Mirapex Er was authorised for market use on 19 February, 2010.
Mirapex Er is available in tablet, extended release;oral dosage forms.
Mirapex Er can be used as treatment of parkinson's disease.
The generics of Mirapex Er are possible to be released after 08 September, 2029.
Market Authorisation Date: 19 February, 2010
Treatment: Treatment of parkinson's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic